Murguía PJG, Arce CDD

Language: Spanish
References: 21
Page: 20-26
PDF size: 253.29 Kb.

ABSTRACT

Invasive fungal infection (IFI) by filamentous fungi causes high morbidity and mortality in patients with hematological diseases and hematopoietic transplant recipients.
Stephanoascus ciferrii is a heterothallic ascomycete yeast-like fungus, which is a teleomorph of Candida ciferrii its isolation in humans is rare, especially in locations other than skin tissues. It has high resistance to fluconazole.
We present the case of an infant diagnosed with high-risk biphenotypic b-cell/myeloid leukemia who presented with intermittent fever, irritability, developmental arrest, and skin nodules on the arm. The profound and prolonged neutropenia conditioned management with broad spectrum antibiotics. In the infectious diagnostic approach and in the event of neurodevelopmental alteration, lumbar puncture was performed; presence of hyphae and yeasts was reported in the cerebrospinal fluid, integrating the diagnosis of proven invasive fungal infection, candidiasis treatment was started according to the guidelines of the Infectious Diseases Society of America (IDSA), with a favorable response.

REFERENCES

1. Lee, H.G., Baek, H.J., Kim, H.S., Park, S.M., Hwang, T.J. yKook, H., “Biphenotypic acute leukemia or acute leukemiaof ambiguous lineage in childhood: clinical characteristicsand outcome”, Blood Res, 2019, 54 (1): 63-73.

2. Torres, G., Mamani, J., Quisbert, Ed., Peñaloza, R.,Miguez, H., Quispe, T., Miranda, M., Cuevas, H. yAmaru, R., “Leucemia bifenotípica aguda b/t: presentaciónde caso clínico”, Cuadernos Hospital deClínicas, 2015, 56 (2): 45-48. Disponible en: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1652-67762015000200007&lng=es&tlng=es.

3. Otto, W.R. y Green, A.M., “Fungal infections in childrenwith haematologic malignancies and stem cell transplantrecipients”, Br J Haematol, 2020, 189 (4): 607-624.

4. Ruiz-Camps, I. y Jarque, I., “Enfermedad fúngica invasorapor hongos filamentosos en pacientes hematológicos”,Revista Iberoamericana de Micología, 2014, 31(4): 249–254.

5. García-Vidal, C. y Salavert Lletí, M., “Inmunopatología delas micosis invasivas por hongos filamentosos”, RevistaIberoamericana de Micología, 2014, 31 (4): 219-228.

6. Menzin, J., Meyers, J.L., Friedman, M., Perfect, J.R.,Langston, A.A., Danna, R.P. et al., “Mortality, length ofhospitalization, and costs associated with invasive fungalinfections in high-risk patients”, Am J Health SystPharm, 2009, 66: 1711-1717.

7. De Gentile, L., Bouchara, J. P., Cimon, B. y Chabasse, D.,“Candida ciferrii: clinical and microbiological features ofan emerging pathogen”, Mycoses, 1991, 34: 125-128.

8. Kreger-Van, N., “Candida ciferri, a new yeast species”,

9. Mycopahol Mycol Appl, 1965, 26: 49-52.De Gentile, L., Boucgara, J., Le Clen’h, C., Cimon, B.,Syomens, F. y Chabasse, D., “Prevalence of Candida ciferriin elderly patients with tropic disorders of the legs”,Mycopathologia, 1995, 131: 99-102.

10. Soki, H., Nagase, Y., Yamazaki, K., Oda, T. y Kikuchi, K.,“Isolation of the yeast-like fungus Stephanoascus ciferriiby culturing the aural discharge of a patient with intractableotitis media. Case report”, Kansenshogaku Zasshi,2010, 84 (2): 210-212.

11. Agin, H., Ayhan, Y., Devrim, I., Gulfidan, G., Tulumoglu,S. y Kayserili, E., “Fluconazole, amphotericin b, caspofungin,and anidulafunginresistant Candida ciferrii: anunknown cause of systemic mycosis in a child”, Mycopathologia,2011, 172: 237-239.

12. Danielescu, C., Cantemir, A. y Chiselita, D., “Successfultreatment of fungal endophthalmitis using intravitrealcaspofungin”, Arq. Bras. Oftalmol, 2017, 80: 196-198.

13. García-Martos, P., Ruiz-Aragón, J., García-Agudo, L.,Saldarreaga, A. Lozano, M. y Marín, P. “Aislamiento deCandida ciferrii en un paciente inmunodeficiente”, RevIberoam Micol, 2004, 21: 85-86.

14. De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A.,Edwards, J.E., Calandra, T. et al., “European Organizationfor Research and Treatment of Cancer/Invasive FungalInfections Cooperative Group; National Institute ofAllergy and Infectious Diseases Mycoses Study Group(eortc/msg) Consensus Group. Revised definitions of invasivefungal disease from the European Organizationfor Research and Treatment of Cancer/Invasive FungalInfections Cooperative Group and the National Instituteof Allergy and Infectious Diseases Mycoses StudyGroup (eortc/msg) Consensus Group”, Clin Infect Dis,2008, 46 (12): 1813-1821.

15. Pappas, P.G., Kauffman, C.A., Andes, D.R., Clancy, C.J.,Marr, K.A., Ostrosky-Zeichner, L., Reboli, A.C., Schuster,M.G., Vázquez, J.A., Walsh, T.J., Zaoutis, T.E. y Sobel,J.D., “Clinical practice guideline for the managementof candidiasis: 2016 update by the Infectious DiseasesSociety of America”, Clin Infect Dis, 2016, 62 (4): e1-50.

16. Fisher, B.T., Robinson, P.D., Lehrnbecher, T., Steinbach,W.J., Zaoutis, T.E., Phillips, B. y Sung, L., “Risk factorsfor invasive fungal disease in pediatric cancer and hematopoieticstem cell transplantation: a systematicreview”, J Pediatric Infect Dis Soc, 2018, 7 (3): 191-198.

17. Reboli, A.C., Rotstein, C., Pappas, P.G., Chapman, S.W.,Kett, D.H., Kumar, D., Betts, R., Wible, M., Goldstein,B.P., Schranz, J., Krause, D.S. y Walsh, T.J., “AnidulafunginStudy Group. Anidulafungin versus fluconazole forinvasive candidiasis”, N Engl J Med, 2007, 356 (24):2472-2482.

18. Reboli, A.C., Shorr, A.F., Rotstein, C., Pappas, P.G., Kett,D.H., Schlamm, H.T., Reisman, A.L., Biswas, P. y Walsh,T.J., “Anidulafungin compared with fluconazole fortreatment of candidemia and other forms of invasivecandidiasis caused by Candida albicans: a multivariateanalysis of factors associated with improved outcome”,bmc Infect Dis, 2011, 11: 261.

19. Rosanova, M.T., Bes, D., Serrano Aguilar, P., CuéllarPompa, L., Sberna, N. y Lede, R., “Efficacy and safetyof caspofungin in children: systematic review and meta-analysis”, Arch Argent Pediatr, 2016, 114 (4): 305-312.

20. Guo, P., Wu, Z., Liu, P., Chen, Y., Liao, K., Peng, Y. y He,Y., “Identification and antifungal susceptibility analysisof Stephanoascus ciferrii complex species isolated frompatients with chronic suppurative otitis media”, FrontMicrobiol, 2021, 12: 680060.

21. Blyth, C.C., Hale, K., Palasanthiran, P., O’Brien, T. y Bennett,M.H., “Antifungal therapy in infants and childrenwith proven, probable or suspected invasive fungalinfections”, Cochrane Database Syst Rev, 2010, (2):cd006343.